Introduction
Most previous investigators have reported that wild-type p53 gene plays a key role on cell cycle control and apoptosis, especially in stressed cell treated by irradiation, cytotoxicity agents or hyperthermia, and inhibits proliferation of tumor cell. Hyperthermia kills tumor cells via a way of inducing cell cycle arrest and apoptosis. Wild-type p53 promotes heat-inducing cell cycle arrest and apoptosis of tumor cells, therefore, enhances intrinsic thermosensitivity of tumor cells. While cells having mutant or vect p53 gene abrogate this response and increase resistance to heat stress 1) 2). p53 gene mutation occuring in more than 50% of all human tumors induces incurable to hyperthermia. Thus, adenovirus-mediated wild-type p53 (Adp53) restoring wild-type p53 gene into tumor cells which have p53 abnormality becomes a strategy in cancer gene therapy combined with radiotherapy or chemotherapy or hyperthermia 4). Replication-deficient adenovirus are most widely used vectors in gene therapy. Because this vector can accept a large size of foreign gene (up to 7.5 kb) and high titers of viruses generally can be obtained with simple method to purify and concentrate adenovirus without loss of infectivity. The high efficacy of infection of most tumors cell lines, which leads to up to 100% gene transfer in cell's nuclear, hasn't any heredity toxicity on host and makes adenovirus highly advantageous if compared with other transfection agents 5) 6). We have previously demonstrated that wild-type p53 promotes S arrest and apoptosis of tumor cells following hyperthermia, therefore, enhances intrinsic thermosensitivity of gastric carcinoma cells lines °. Adenoviral p53 gene therapy promotes heat-inducing apoptosis in a nasopharyngeal carcinoma cell line 7). In the current study, wild-type p53 gene transfer into the two gastric carcinoma cell lines with different p53 genetic status was performed using the Adp53 to evaluate the effect of wild-type p53 on heat-induced apoptosis and thermosensitivity compared to that receive with hyperthermia alone in vitro and in vivo. In addition, we also conducted a phase II clinical trial on Adp53 (Gendicine R ) combined with hyperthermia in Beijing Cancer Hospital. received multiple intratumoral injection of Gendicine , no dose-limiting toxicity and adverse events were noted, except transient fever was the most common finding.
Gendicine R Combined with Hyperthermia
Meantime 7 patients with advanced cancer confirmed by patho-histological examination were intratumorally injected with Gendicine 1 X 1012 vp/ml once a week over to eight, concurrently 3 days later combined with hyperthermia alone for 3 patients, and plus radiotherapy for 4 patients. Case 1 patient, female, 69 years, with recurrent thyroid cancer. Post-operation 9 months later, neck local recurrent tumor failed in radio-chemo-hyperthermia was US-guided injected with Gendicine R 1 X 1012 vp/ml once a week over to eight, concurrently 3 days later combined with hyperthermia alone at 42 using 915MHz machine over to eight. 
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